Floatz logo

Evolocumab

Stroke

Amgenmonoclonal_antibodyPhase 4 / ApprovedActive
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
65/ 100

Competitive context

132 Active assets in the Stroke cohort.

Asset / SponsorPhaseRating
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
Aggrenox
Boehringer Ingelheim
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Rivaroxaban
China National Center for Cardiovascular Diseases
Phase 4BBB

View all 50 →

Same molecule, other indications

Evolocumab is also rated in:

Acute StrokeDormant
BB
Indicative ·
67 / 100
View asset →
cardiovascular disorderDormant
B
Indicative ·
63 / 100
View asset →
myocardial infarctionDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →